Monitor this situation.

Unsubscribe anytime.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 4 sources · 12 days · First seen 15 days ago · Last updated 4 days ago

Japanese biotechnology funding for cancer research

Overview

Japanese biotechnology ventures are securing funding to advance nucleic acid-based cancer research and diagnostics.

MiRNDa, Inc. completed a seed funding round led by Takanawa Gateway Global Benefit Investment Limited Partnership and Meiji Yasuda Future Co-creation Investment Limited Partnership. The Tokyo-based startup intends to use the capital to accelerate research into RNA modification analysis technology for the early detection of difficult-to-identify cancers, such as pancreatic and liver cancers.

Separately, ANRis raised approximately 220 million yen from Waseda University Ventures and the Japan Science and Technology Agency. The company is utilizing its ‘SNPD-siRNA’ technology to target KRAS mutation cancers associated with lung, pancreatic, and colorectal cancers. The funds are designated for drug candidate creation, non-clinical research, drug delivery system optimization, and talent acquisition.

Entities

Waseda University Ventures · Global Brain Co., Ltd. · Masaki Hirose · MiRNDa, Inc. · Japan Science and Technology Agency

Timeline

4 days ago

[BUSINESS] 2 sources
ANRis raises 220 million yen for KRAS mutation cancer drug development
Japanese biotech startup ANRis has raised 220 million yen to develop siRNA therapies targeting KRAS mutation cancers using its unique single-nucleotide discrimination technology.
15 days ago

[BUSINESS] 3 sources
MiRNDa, Inc. secures seed funding for RNA-based cancer detection
Tokyo startup MiRNDa, Inc. has secured seed funding to advance its proprietary RNA modification analysis technology for the early detection of difficult-to-diagnose cancers.

Sources

ascii.jp · kepple.co.jp · prtimes.jp · thebridge.jp